EPICPROST

What is EpicProst

Precision diagnosis for prostate cancer.

EpicProst is an innovative test developed through collaboration between researchers in Germany and Brazil.

Based on epigenetic DNA markers, it allows identification of a tumor's invasiveness and recurrence potential — something that PSA tests and traditional biopsies cannot predict with the same level of accuracy.

How the test works

Science that reveals the tumor's real behavior.

  • Epigenetic analysis of the hTERT gene: detects specific alterations associated with telomerase activity, present only in cancer cells.
  • High sensitivity and specificity: identifies aggressive tumors and reduces false positives.
  • Can be performed on tissue or blood samples: a minimally invasive method, also known as liquid biopsy.
  • Strong scientific foundation: developed from peer-reviewed studies and international validations.

Why take the EpicProst test

Fewer uncertainties. Safer decisions.

  • Differentiates dangerous tumors from harmless ones.
  • Reduces unnecessary surgeries and treatments.
  • Provides valuable information on aggressiveness and risk of recurrence.
  • Supports the choice between active treatment or minimally invasive therapies, such as HIFU.

Who is EpicProst for?

Designed for those seeking diagnostic precision.

The test is recommended for patients already diagnosed with prostate cancer who wish to better understand the tumor's aggressiveness and define the most appropriate clinical approach together with their physician.

Key points:
  • Men with a positive biopsy result.
  • Patients evaluating treatment options.
  • Physicians seeking reliable diagnostic support.

Scientific foundation

Built on decades of international scientific research.

EpicProst was born from a collaboration between Universidade Positivo (Curitiba, Brazil) and Heinrich Heine University (Düsseldorf, Germany).

Its development has been documented in multiple peer-reviewed publications, with clinical validations confirming high sensitivity and reproducibility.

Internal validation

95% accuracy in control samples.

External validation

100% accuracy in independent European analyses.

Patents registered in Brazil and Europe.

Results and clinical impact

Knowledge that transforms medical decisions.

EpicProst delivers information that goes beyond diagnosis.

It supports treatment decisions based on the tumor's molecular behavior, helping doctors and patients avoid unnecessary radical treatments.

Accurate diagnosis

High precision in detecting and differentiating tumors.

Therapeutic guidance

Supports safer clinical decisions.

Personalized prognosis

Predicts recurrence risk.

Improved quality of life

Helps reduce side effects such as impotence and incontinence.

FAQ about EpicProst

Questions about EpicProst? Check out the answers.

An epigenetic test that analyzes molecular alterations in the hTERT gene, associated with prostate cancer aggressiveness.
It can be performed using prostate tissue or a blood sample (liquid biopsy).
It indicates the presence of cancer and provides insights into its aggressiveness, supporting safe medical decisions.
No. It complements them, offering a level of precision these exams cannot reach.
Yes. EpicProst was developed based on peer-reviewed research and validated in international centers.

Leave your contact details to receive updates.

DOHMS